Fauci says Pfizer, Moderna Covid vaccine data is 'solid'

Cornelia Mascio
Novembre 20, 2020

The share price of Pfizer gained significantly on Thursday after the American pharmaceutical corporation (Pfizer Inc) said that the final results from the late-stage trial of its COVID-19 vaccine were 95 percent effective. "Today is a special day", Bucci said.

Traditional virus vaccines use actual viruses that can take months or years to develop.

"This will not replace hygienic measures - it will be an adjunct to hygienic measures", Dr. Paul Offit, a professor at the University of Pennsylvania and a member of the Federal Drug Administration's vaccine advisory panel, recently underscored to the Times.

Pfizer CEO Albert Bourla said Tuesday that the company had reached a key milestone in security data and would request emergency use authorization in the US.

This was followed by data on a vaccine made by USA company Moderna suggesting almost 95% protection and similarly promising results from trials of another developed in Russian Federation, called Sputnik.

The final analysis data of the trial indicated that the vaccine had an efficacy rate of 95% in participants without prior SARS-CoV-2 infection, which was the first primary objective, in each case after seven days of administering second vaccine dose.

The twin breakthroughs have lifted hopes for an end to a pandemic that has infected more than 56 million people and caused over 1.3 million deaths worldwide since the virus first emerged in China late past year. "This is really solid", Fauci continued.

The submission to the FDA is based on results from the Phase 3 clinical trial of Pfizer's vaccine, which began in the United States on July 27 and enrolled more than 43,000 volunteers.

The duo expects to produce up to 50 million doses of the two-shot vaccine regimen in 2020, with up to 1.3 billion doses to follow in 2021, Pfizer said earlier this month.

Pfizer, Moderna COVID vaccines could be ready for US use in weeks
Pfizer reports COVID-19 vaccine 95% effective as Phase 3 trial concludes

Fauci said the coronavirus vaccines quickly created by Moderna and Pfizer are the result of "extraordinary" advances in medicine and the developers did not compromise safety or scientific integrity.

While some groups such as healthcare workers will be prioritized in the United States and Britain for vaccinations, it will be months before large-scale rollouts begin in either country.

It has also ordered 100 million doses of the Oxford-AstraZeneca vaccine, which is planning to release data from its phase three trial soon. "So, that means that certain vaccinators will have to deliver that vaccine", she said.

Pfizer, which said Wednesday it is on the verge of seeking FDA review, has reported that its vaccine is more than 94% effective in adults over 65.

Just eight were in the group given the vaccine, suggesting it offers good protection. The most common adverse event rated as "severe" in the trial was fatigue, in 3.7 percent of participants after the second dose.

The Pfizer vaccine must be stored at about minus 80C, although it can be kept in a fridge for five days. The Pfizer and BionTech vaccine went into tests shortly thereafter.

An emergency authorization for a vaccine is typically a lower standard than full approval. Older patients had fewer and milder side-effects.

According to Bloomberg News, both vaccines rely on a technology called messenger RNA, which, until now, has never been used to build an approved vaccine.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE